GSK plc's 5-in-1 meningococcal vaccine, Penmenvy, received FDA approval on February 15, 2025, for individuals aged 10 to 25, targeting five serogroups of Neisseria meningitidis. This approval aims to improve vaccination rates among adolescents and young adults.